HR Execs on the Move

HealthEast Care System

www.healtheast.org

 
HealthEast Care System is a community-focused, nonprofit healthcare system that provides a full spectrum of HealthEast Care System is a community-focused, nonprofit healthcare system that provides a full spectrum of family health services. Hospitals include St. Joseph`s Hospital, St. John`s Hospital, Woodwinds Health Campus and Bethesda Rehabilitation Hospital. Other services include hospitals, physician clinics, senior care centers, rehabilitation facilities, hospice, home care, outpatient surgery centers, and a variety of other health facilities and programs. HealthEast has approximately 7,500 employees and has more than 1,300 physicians on staff. Locally owned and operated, HealthEast is the largest health care provider in the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Alicia Kroll
Director of Leadership Development and Organizational Effectiveness Profile

Similar Companies

Tom Bass Regional Park

Precinct One has 1.1 million residents. County Commissioners operate parks, build road/bridge projects and offer senior and youth programs.

Wolters Kluwerhealth

Wolters Kluwerhealth is a Ambler, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIO 101

BIO 101 is a Vista, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

VitaPath Genetics

VitaPath Genetics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.